Abstract
Parkinsons disease (PD) is characterized by the selective loss of dopamine (DA) neurons in the substantia nigra compacta (SNc). The transcription factor Pitx3 is important for the differentiation and maintenance of midbrain DA neurons during development. There is highly restricted and constitutive expression of Pitx3 in the SNc and ventral tegmental area (VTA) of the midbrain after birth. In addition to its importance during development, Pitx3 also has roles in the long-term survival and maintenance of the midbrain DA neurons. In this review, we discuss the function of Pitx3 throughout the life of midbrain neurons and the contribution of Pitx3 to disease mechanisms.
Keywords: Mesostriatal, substantia nigra, pituitary homeobox, transcription factor 3, Rieg1, parkinsonian, Nurr1, aphakia
Current Topics in Medicinal Chemistry
Title: The Role of Transcription Factor Pitx3 in Dopamine Neuron Development and Parkinsons Disease
Volume: 9 Issue: 10
Author(s): Jia Li, John A. Dani and Weidong Le
Affiliation:
Keywords: Mesostriatal, substantia nigra, pituitary homeobox, transcription factor 3, Rieg1, parkinsonian, Nurr1, aphakia
Abstract: Parkinsons disease (PD) is characterized by the selective loss of dopamine (DA) neurons in the substantia nigra compacta (SNc). The transcription factor Pitx3 is important for the differentiation and maintenance of midbrain DA neurons during development. There is highly restricted and constitutive expression of Pitx3 in the SNc and ventral tegmental area (VTA) of the midbrain after birth. In addition to its importance during development, Pitx3 also has roles in the long-term survival and maintenance of the midbrain DA neurons. In this review, we discuss the function of Pitx3 throughout the life of midbrain neurons and the contribution of Pitx3 to disease mechanisms.
Export Options
About this article
Cite this article as:
Li Jia, Dani A. John and Le Weidong, The Role of Transcription Factor Pitx3 in Dopamine Neuron Development and Parkinsons Disease, Current Topics in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/156802609789378236
DOI https://dx.doi.org/10.2174/156802609789378236 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology Endothelial Cell Regulation of Cardiac Metabolism Following Diabetes
Cardiovascular & Hematological Disorders-Drug Targets Clarithromycin Attenuates Left Ventricular Remodeling and Dysfunction after Pressure Overload in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science By Discontinuing Beta-Blockers Before an Exercise Test, We may Precipitate a Rebound Phenomenon
Current Vascular Pharmacology Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update
Current Pharmaceutical Design From Genomic Imprinting to Developmental Physiology: Identifying Stepping Stones
Current Pharmacogenomics Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Carotid Artery Disease: Current Concepts on Endothelial Dysfunction and Matrix Remodeling
Current Drug Therapy Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Glutamate and Psychosis Risk
Current Pharmaceutical Design Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology